Safety, Pharmacokinetic and Efficacy Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Patients With Primary Immunodeficiency (Hypo- or Agammaglobulinemia)

NCT00161993 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Immunodeficiency Diseases (PID)
Agammaglobulinemia
Hypogammaglobulinemia

Interventions

DRUG: Immune Globulin Intravenous (Human), 10% TVR (Triple Virally Reduced) Solution
DRUG: Gammagard S/D (Solvent/Detergent)

Sponsor

Baxalta now part of Shire